CASI to receive a $10M up front, milestones along with royalty. Tianshi will complete its first equity financing then CASI will hold 15% of Tianshi’s equity at $3M through its wholly-owned PRC subsidiary upon completion of equity investment. Tianshi to receive $17.98M from 2 venture capital investors
Tianshi gets an exclusive license globally for CID-103 in autoimmune diseases & disorders in humans while CASI will retain exclusive commercialization & co-marketing rights to CID-103 in the same indication along with all revenue generated in the US. In China, CASI owns co-commercial rights to CID-103 for autoimmune-derived hematology & oncology
CID-103 has higher preclinical safety & activity against cancers that express CD38 compared to other CD38 mAbs
Ref: CASI | Image: CASI
